List of Excipients in Branded Drug VAGIFEM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	VAGIFEM	estradiol	54868-6182	HYPROMELLOSES

Vagifem Excipient Strategy and Commercial Opportunities in Vaginal Estradiol

Last updated: August 9, 2026

Vagifem is a low-dose vaginal estradiol tablet used for moderate-to-severe vulvar and vaginal atrophy associated with menopause. Its commercial position depends less on the estradiol molecule, which is genericized, than on low-dose uniformity, vaginal retention, applicator design, tolerability, manufacturing consistency, and regulatory differentiation. The strongest opportunities are in preservative-free local estrogen delivery, simplified administration, lower-waste applicators, patient-friendly formulations, and products that improve dissolution without increasing systemic exposure.

What is Vagifem and how is it formulated?

Vagifem is a vaginal insert containing estradiol. The current U.S. product is commonly marketed in a 10 mcg strength, administered intravaginally with a disposable applicator. The product is manufactured by Novo Nordisk under the Vagifem brand in the United States.[1]

The labeled inactive ingredients for Vagifem 10 mcg include:

Component	Functional role
Lactose monohydrate	Diluent and tablet bulking agent
Maize starch	Disintegrant and binder-support excipient
Hypromellose	Binder and film-forming polymer
Magnesium stearate	Lubricant
Film-coating components	Surface protection, handling, appearance and swallowability is not relevant because the product is not orally administered

The vaginal tablet is designed to deliver a very small quantity of estradiol while maintaining physical integrity during packaging, handling and insertion. The formulation must disintegrate and release drug after vaginal administration without creating excessive residue or producing an unacceptable sensation.

Vagifem is distinct from vaginal estradiol creams, rings and softgel inserts. A tablet requires more careful control of compression force, porosity, disintegration, moisture and content uniformity than a liquid cream. The product also has a device component because administration depends on an applicator.

What excipient strategy does Vagifem use?

Vagifem uses a conventional direct-compression or compression-oriented tablet excipient platform centered on lactose, starch, hypromellose and magnesium stearate. That composition is commercially attractive because the ingredients are widely available, inexpensive and supported by extensive pharmaceutical use.

Lactose monohydrate

Lactose provides bulk for a 10 mcg dose. Without a diluent, the tablet would be too small for reliable manufacturing and handling. Lactose also supports acceptable compression and tablet weight uniformity.

The main commercial risks are lactose intolerance concerns, although vaginal administration materially differs from oral lactose exposure, and supplier variability in particle size, moisture and flow characteristics. A generic or reformulated product could replace lactose with mannitol, microcrystalline cellulose, dibasic calcium phosphate or a co-processed filler.

Maize starch

Maize starch helps the tablet break apart after exposure to vaginal fluid. Disintegration is commercially important because a compact tablet that remains intact can delay drug release and reduce dose dispersion.

Starch levels must be balanced against tablet hardness. Excessive disintegrant can increase friability, dust and residue. Insufficient starch can produce slow or incomplete disintegration.

Hypromellose

Hypromellose acts as a binder and can support film coating. In a low-dose vaginal tablet, polymer level and grade affect compression behavior, tablet strength, hydration and release.

Hypromellose is also a potential platform for differentiated products. A manufacturer could use a higher-viscosity grade, a lower-substitution grade or a different hydrophilic polymer to alter residence time. Such changes would require comparative dissolution and local tolerability data because a longer-residence formulation may increase residue or irritation.

Magnesium stearate

Magnesium stearate improves powder flow and prevents adhesion during compression. Its concentration and mixing time are important. Over-lubrication can reduce tablet tensile strength, slow wetting and impair dissolution. The effect is particularly relevant when the active ingredient represents only 10 mcg of the finished tablet.

A commercial developer seeking faster disintegration could evaluate sodium stearyl fumarate or a lower level of magnesium stearate. Any substitution would require evidence that assay, content uniformity, dissolution and stability remain within specification.

What excipients could improve on the Vagifem formulation?

The most credible opportunities involve formulation optimization rather than a radically new excipient.

Opportunity	Candidate approach	Commercial rationale	Main development issue
Faster disintegration	Crospovidone, croscarmellose sodium or sodium starch glycolate	Faster drug release and less intact-tablet residue	Need to control swelling and local sensation
Lactose-free product	Mannitol, microcrystalline cellulose or dibasic calcium phosphate	Supports patient segmentation and procurement flexibility	May change tablet size, hardness and moisture behavior
Improved low-dose uniformity	Ordered mixing, spray-dried carrier or co-processed excipient	Reduces segregation of estradiol during manufacture	Requires robust content-uniformity validation
Lower-residue tablet	More porous compression or direct-compression mannitol	May improve patient experience	Higher friability and packaging risk
Longer vaginal residence	Mucoadhesive polymers such as carbomer or selected cellulose derivatives	May reduce leakage and dosing frequency	Could increase irritation, residue or systemic exposure
Moisture protection	High-barrier blister and desiccant-controlled packaging	Protects low-dose stability	Packaging changes may require stability and device validation
Preservative-free delivery	Solid tablet, insert or softgel	Avoids preservative-related tolerability concerns	Must demonstrate microbiological and stability control
Applicator optimization	Reduced-plastic, prefilled or reusable device	Creates product-level differentiation	Device classification, human factors and environmental claims

The highest-probability near-term strategy is a lactose-free, rapidly disintegrating, preservative-free vaginal insert using established compendial excipients. This approach can create a differentiated product without relying on an untested novel polymer.

What formulations compete with Vagifem?

Vagifem competes with several local estrogen dosage forms and with non-estrogen products for genitourinary syndrome of menopause.

Product or category	Active ingredient	Dosage form	Key differentiation
Vagifem	Estradiol	Vaginal tablet/insert	Low-dose solid dosage form with applicator
Generic estradiol vaginal inserts	Estradiol	Vaginal insert/tablet	Lower price and similar therapeutic objective
Estradiol vaginal cream	Estradiol	Cream	Flexible dosing but messier administration
Estring	Estradiol	Vaginal ring	Extended residence and infrequent replacement
Imvexxy	Estradiol	Vaginal softgel insert	Soft, low-dose insert and applicator-based administration
Premarin vaginal cream	Conjugated estrogens	Cream	Different estrogen composition and flexible dosing
Intrarosa	Prasterone	Vaginal insert	Non-estrogen active ingredient converted locally to sex steroids
Osphena	Ospemifene	Oral tablet	Systemic non-estrogen selective estrogen receptor modulator

Imvexxy is the most relevant formulation comparator because it competes directly on low-dose vaginal administration, convenience and patient comfort. Estring competes on dosing frequency. Creams compete on flexibility and price but have higher handling inconvenience.

What commercial opportunities exist for Vagifem-like products?

1. Generic and authorized-generic supply

The primary opportunity is a lower-cost estradiol vaginal insert with equivalent strength, release and administration performance. FDA approval requires pharmaceutical equivalence and bioequivalence or another acceptable evidence package under the applicable abbreviated new drug application pathway.[2]

A generic manufacturer can compete through:

• Lower manufacturing cost
• Dual-source excipient procurement
• Automated tablet inspection
• More efficient applicator assembly
• Lower-cost secondary packaging
• Supply reliability during shortages or allocation events

The active ingredient is inexpensive. The main cost drivers are low-dose manufacturing controls, applicator production, packaging, quality testing and regulatory maintenance.

2. Device-led differentiation

The applicator is a meaningful commercial variable. A developer could reduce applicator size, eliminate unnecessary plastic, improve grip, introduce a preloaded single-step system or offer a reusable device with separately packaged inserts.

Device changes can generate intellectual-property value even when the estradiol formulation is not novel. However, the device must undergo human-factors evaluation and combination-product review where applicable. Claims about reduced waste must be supported by life-cycle and packaging data.

3. Lactose-free or excipient-sensitive positioning

A lactose-free formulation could target patients and clinicians who prefer to avoid lactose-containing products. The commercial value is likely to be segment-specific rather than broad-market. The label must state the actual excipient composition and cannot imply clinical superiority without supporting evidence.

A lactose-free product would need to preserve:

• 10 mcg assay accuracy
• Content uniformity
• Rapid and reproducible disintegration
• Stability through the labeled shelf life
• Acceptable tablet size and mechanical strength

4. Extended-residence inserts

A mucoadhesive tablet, gel-forming insert or bioadhesive softgel could seek reduced leakage and less frequent administration. This strategy has greater commercial upside than a simple excipient substitution but also carries higher development risk.

A longer-residence product must address vaginal irritation, discharge, local microbiome effects, systemic estradiol exposure and patient removal requirements. A formulation that remains in place longer may not be clinically preferable if it produces residue or discomfort.

5. Combination and adjunctive products

Potential combinations include estradiol with moisturization, pH modulation or barrier-support functionality. These products require careful regulatory classification. Adding a nonactive excipient with a physiological claim can move a product toward combination-product or drug-device analysis.

A clinically meaningful combination with an antifungal, antimicrobial or microbiome-directed agent would face substantially higher interaction, safety and regulatory requirements. Such products are less attractive than incremental solid-dose improvements unless they solve a defined unmet need.

When does Vagifem lose exclusivity?

Vagifem’s original small-molecule and formulation exclusivity periods have expired in the United States. Generic estradiol vaginal inserts have entered the market, and the product no longer depends on an unchallenged brand-only position.[2,3]

The relevant commercial protections are now more likely to involve:

• Product-specific formulation patents
• Applicator or packaging patents
• Manufacturing process patents
• Trademarks and trade dress
• Regulatory exclusivity for any newly approved reformulation
• Contractual supply arrangements
• Clinical-data differentiation

Patent expiry should be assessed against the current FDA Orange Book listing and the exact product strength, dosage form and NDA. Orange Book patent records can change as patents are added, delisted or reexamined.[3]

What patents protect Vagifem and its excipient strategy?

The original Vagifem estate was directed primarily to vaginal estradiol dosage forms, low-dose delivery and related manufacturing or product features. Any remaining enforceable protection must be separated from expired patents and from claims that do not cover a proposed generic product.

For a new entrant, the most relevant freedom-to-operate questions are:

1. Does the product use the same estradiol strength and dosage form?
2. Does it use a claimed tablet composition or excipient ratio?
3. Does it use a protected applicator geometry or insertion mechanism?
4. Does it practice a patented manufacturing process?
5. Does the proposed label rely on a protected method of use?
6. Does the product infringe patents listed for the relevant NDA or patent-family members in other jurisdictions?

Excipient substitutions can reduce composition-claim risk, but they do not automatically avoid process or device claims. A lactose-free product may avoid a lactose-specific claim while remaining exposed to broad claims covering estradiol vaginal inserts.

How strong is the current Vagifem patent estate?

The original brand patent position is weaker than it was before generic entry because estradiol is an old active ingredient and the core dosage-form concept is established. The remaining strategic value is concentrated in narrow claims covering specific compositions, applicators, manufacturing controls or improved release profiles.

A practical risk ranking is:

IP category	Relative risk to a generic entrant	Reason
Estradiol molecule	Low	Long-established active ingredient
Basic vaginal tablet concept	Low to medium	Broad concept is mature
Exact excipient ratio	Medium	May matter if claims remain enforceable
Mucoadhesive or controlled-release system	Medium to high	Novel formulation claims may be narrower but valuable
Applicator design	Medium	Device changes can create separate infringement exposure
Manufacturing process	Medium	Process claims may affect production site and scale-up
Method of use	Low to medium	Depends on listed claims and proposed labeling

The commercial moat is therefore more likely to be operational and device-based than dependent on a broad active-ingredient patent.

What is the FDA and Orange Book status of Vagifem?

Vagifem is an FDA-approved prescription drug marketed as a vaginal estradiol product. The reference product is associated with NDA 021367, while generic versions are approved through ANDA pathways.[1-3]

The Orange Book is the principal source for:

• Reference-listed drug status
• Approved strengths
• Dosage-form information
• Listed patents
• Pediatric exclusivity, if applicable
• Therapeutic-equivalence codes for approved generic products

FDA approval of a generic vaginal estradiol insert does not automatically establish interchangeability with every other local estrogen product. Creams, rings, tablets, softgel inserts and oral products have different dosage forms and may have different therapeutic-equivalence considerations.

Which companies are challenging or competing with Vagifem?

Competition includes generic manufacturers of estradiol vaginal inserts and branded developers of alternative local estrogen products. The relevant competitive groups are:

• Generic manufacturers offering estradiol vaginal inserts
• Novo Nordisk as the Vagifem brand owner
• TherapeuticsMD or successor commercial interests associated with Imvexxy
• Pfizer and related commercial interests associated with Estring
• AbbVie and related commercial interests associated with Premarin vaginal cream
• Endoceutics and related commercial interests associated with Intrarosa

The commercial contest is based on price, prescribing familiarity, pharmacy coverage, applicator convenience, patient persistence and perceived local tolerability. A lower price alone may not displace a branded product if the generic has a less convenient applicator or weaker distribution.

What generic launch risks exist for Vagifem?

A generic launch faces five main risks:

• Low-dose content-uniformity failures caused by estradiol segregation
• Dissolution differences caused by lubricant level, compression force or polymer grade
• Applicator breakage, dimensional variation or poor human-factors performance
• Stability failures caused by moisture ingress
• Market erosion from multiple generic entrants

The optimal manufacturing strategy uses controlled blending, validated low-dose sampling, in-process weight and hardness controls, dissolution trending, high-barrier packaging and applicator inspection. A supplier-change plan is important because lactose, starch, hypromellose and magnesium stearate can vary in particle size, moisture and functionality.

What licensing opportunities exist around Vagifem-like products?

Licensing opportunities are more credible in platform technologies than in the legacy Vagifem composition itself. Potential assets include:

• Low-dose vaginal insert manufacturing technology
• Bioadhesive polymers with local tolerability data
• Sustainable applicators
• Prefilled or reusable delivery systems
• Spray-dried or co-processed excipient platforms
• Regional generic commercialization rights
• Contract manufacturing capacity for vaginal tablets and combination products

A licensee should value these assets against the cost of demonstrating bioequivalence, device compatibility, stability and commercial scale. A novel excipient with no prior vaginal use may increase regulatory burden enough to eliminate the expected margin advantage.

Key Takeaways

• Vagifem uses a conventional excipient system based on lactose monohydrate, maize starch, hypromellose and magnesium stearate.
• The core estradiol opportunity is genericized; differentiation must come from formulation performance, device design, packaging or supply economics.
• The strongest near-term opportunity is a lactose-free, preservative-free, rapidly disintegrating vaginal insert with a lower-waste applicator.
• Extended-residence and mucoadhesive systems offer greater upside but require more extensive local safety and performance evidence.
• The principal IP risks are narrow formulation claims, applicator patents and manufacturing-process claims.
• FDA Orange Book and current patent-family review remain central to product-specific freedom-to-operate analysis.
• Manufacturing control is commercially important because the 10 mcg dose creates segregation, assay and content-uniformity challenges.

FAQs

Can a Vagifem generic use different excipients?

Yes. A generic may use different inactive ingredients if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, labeling and safety. The substitute excipients must not materially alter performance or create unacceptable local exposure.

Is a lactose-free Vagifem alternative commercially attractive?

It can be attractive as a targeted differentiation strategy, particularly for institutional formularies and patients seeking lactose-free products. Its value depends on whether the alternative maintains tablet strength, rapid disintegration and low-dose uniformity without increasing manufacturing cost.

Are vaginal estradiol tablets easier to manufacture than creams?

No. The active dose is very small, and the tablet requires tight control of blending, compression, assay and content uniformity. Creams have different challenges, including emulsion stability, microbial control and dose-delivery consistency.

Can an improved Vagifem applicator receive separate patent protection?

Yes. Novel applicator geometry, insertion control, dose presentation, material configuration or reuse features may support device claims. Protection depends on novelty, nonobviousness, claim scope and the specific implementation.

Could a mucoadhesive Vagifem replacement reduce dosing frequency?

Potentially, but the claim would require product-specific evidence. A longer residence time does not automatically establish reduced dosing frequency, better efficacy or improved adherence. Local irritation, residue and systemic exposure would need evaluation.

References

1. Novo Nordisk. (2023). Vagifem 10 mcg vaginal insert: U.S. prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, NDA 021367.
4. U.S. Food and Drug Administration. (2020). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
5. North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794.